Navigation

PRESS RELEASES

American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference

American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference

By AGT | Jan 7, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, January 7, 2019 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 7-10 in San Francisco, California. American Gene Technologies invitation to attend the conference follows recent discussions with J.P. Morgan and other biotechnology investment firms about AGT’s significant… [Read More]

American Gene Technologies Granted FDA Orphan Drug Designation For Phenylketonuria

By AGT | Oct 18, 2018
Filed Under:

ROCKVILLE, MD, UNITED STATES, October 18, 2018 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy company in the discovery and development of lentiviral vector based therapeutics, announces that the U.S. Food and Drug Administration (FDA) received orphan-drug designation #DRU-2018-6572 for the treatment of phenylketonuria (PKU) using its proprietary, lentiviral vector based technology. PKU is a debilitating inherited… [Read More]

American Gene Technologies to Present at 2018 Cell and Gene Meeting On The Mesa

By AGT | Sep 26, 2018
Filed Under:

ROCKVILLE, MD, UNITED STATES, September 26, 2018 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, California. Dr. Pauza’s presentation will cover recent progress on AGT’s HIV cure and gamma delta T cell immuno-oncology… [Read More]

Immunotherapy CEO Jeff Galvin Joins The Board of Directors of the Cancer Support Community

By AGT | Sep 6, 2018
Filed Under:

ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ — Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC). Galvin’s biotech company, American Gene Technologies International Inc. (AGT), is striving to create the next big revolution… [Read More]

American Gene Technologies (AGT) Granted Three New Patents in its HIV Cure and Immuno-oncology Programs

By AGT | Aug 22, 2018
Filed Under:

ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ — AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors (“Methods and Composition for the Activation of Gamma Delta T cells” US10023880 and US10036040). The… [Read More]

American Gene Technologies CEO Jeff Galvin Joins Maryland Tech Council Board of Directors

By AGT | Aug 20, 2018
Filed Under:

ROCKVILLE, MD, UNITED STATES, August 20, 2018 /EINPresswire.com/ — American Gene Technologies International Inc. (AGT)’s CEO and founder Jeff Galvin has been appointed to the Board of Directors of the Maryland Tech Council, the largest Maryland technology trade association, representing over 600 companies across the breadth of technology and life science industries. Galvin stated: “I am honored to contribute to… [Read More]

American Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention

By AGT | Apr 30, 2018
Filed Under:

ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today congratulates Robert R. Redfield, M.D., on his appointment as the Director of the Centers for Disease Control and Prevention (CDC). Dr. Redfield has served as an advisor to AGT since 2011 and later became chair of the Clinical Advisory Board… [Read More]

American Gene Technologies Gains Additional Immuno-Oncology Patent

By AGT | Mar 19, 2018
Filed Under:

Novel approach to activating gamma delta T cells shows promise in animal studies — demonstrating efficacy in multiple epithelial solid tumors and metastases ROCKVILLE, Md., March 19, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced receipt of a second immuno-oncology patent on the stimulation of gamma delta T cells for… [Read More]

American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV cure

By AGT | Jan 29, 2018
Filed Under:

Completes process development for the AGT103-T automated cell manufacturing protocol ROCKVILLE, MD, January 25, 2018 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV cure automated cell processing protocol. This completes a key milestone of AGT’s planned Phase I clinical trial of AGT103-T, a genetically modified… [Read More]

American Gene Technologies Receives U.S. Patent on Novel Immuno-Oncology Methods of Treating Cancer through Activation of Gamma Delta T Cells

By AGT | Dec 12, 2017
Filed Under:

Patent encompasses AGT’s advanced gene and cell therapy strategy for oncology ROCKVILLE, MD, December 12, 2017 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced the issuance of U.S. Patent No: 9,834,790 dated December 5, 2017, covering methods of treating cancer with AGT’s proprietary viral vector technology. The patent recognizes AGT’s unique approach to… [Read More]

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Mailchimp sidebar

Follow AGT on Social Media

Send this to a friend